Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:
Daily Aspirin Not A Good Choice for Healthy People
Taking a daily aspirin to prevent heart disease has more risks than benefits in healthy people, a new study finds.
The researchers reviewed published evidence on the benefits of taking low-dose aspirin, CNN reported. The study was published Wednesday in the British Journal of Clinical Pharmacology.
Researchers concluded that the risk of bleeding caused by aspirin’s blood-thinning effect far outweighed any benefit the drug might have.
Both the American College of Cardiology and the American Heart Association say that only people who have had a heart attack, stroke or open-heart surgery should be taking a daily aspirin.
Researchers found that while a daily aspirin lowered the risk of heart attack or stroke by 17%, the risk for gastrointestinal bleeding was increased by 47% and by 34% for brain bleeding.
“Our paper confirms that there is no evidence for taking aspirin in primary prevention, i.e. in healthy people,” researcher Dr. Lee Smith, a reader in Physical Activity and Public Health at Anglia Ruskin University in the U.K., told CNN.
“The take-home message of our paper is that low dose aspirin is [only] good when you already have a cardiovascular condition,” Smith added.
—–
Certain Genes Linked With Severe COVID-19
Scientists reported Wednesday that they have found links between certain genes and severe COVID-19.
For example, people with type A blood may have higher odds of getting sick, The New York Times reported.
In patients with COVID-19, variations in one stretch of the human genome is tied to a risk of respiratory failure and another with blood type, the scientists discovered.
Type A blood increases the odds of a patient needing oxygen or being put on a ventilator by 50%, the Times reported.
Oddly, genetic changes in the protein the virus needs to infect cells didn’t make a difference in the risk for severe infection.
These findings suggest that unknown factors may play a part in the risk for deadly COVID-19.
“There are new kids on the block now,” researcher Andre Franke, a molecular geneticist at the University of Kiel in Germany, explained to the Times.
—–
Fauci Says Any COVID-19 Vaccine Would Be in Plentiful Supply By 2021
According to Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, 100 million doses of a coronavirus vaccine will be available by year’s end, CNN reported.
“Then, by the beginning of 2021, we hope to have a couple hundred million doses,” Fauci said during a conference with the Journal of the American Medical Association.
It’s still not clear which vaccine will be effective. One vaccine candidate, developed by drug company Moderna and NIAID, will start phase 3 trials by mid-summer, Fauci said.
“The real business end of this all will be the Phase 3 that starts in the first week of July, hopefully,” Fauci said. “We want to get as many data points as we can.”
The phase 3 will include about 30,000 people. A Phase 2 trial started a few days ago, CNN said.
The plan, according to Fauci is to make doses of the vaccine before it’s known if it will work, so if it does work it can be distributed quickly.
Another vaccine from the University of Oxford and AstraZeneca is on a similar schedule, CNN said.
“I’m cautiously optimistic that with the multiple candidates we have with different platforms, that we are going to have a vaccine that will make it deployable,” Fauci said.
He is optimistic, because infected people do develop immune system antibodies against the new coronavirus.
“Which tells us, that if the body is capable of making an immune response to clear the virus of natural infection, that’s a pretty good proof of concept,” Fauci said. “Having said that, there is never a guarantee.”
Copyright © 2024 HealthDay. All rights reserved.